| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $245,356 ) |
| | 2024 | 2024 | PERSPECTUM, INC | 400 OYSTER POINT BLVD | SOUTH SAN FRANCISCO | CA | 94080-1979 | SAN MATEO | USA | U01FD008425 | DDT-BMQ-000146 Assessing clinically meaningful change in PSC as determined by quantitative MRCP (MRCP+) measured number of strictures | 000 | 1 | FDA | 9/2/2024 | $245,356 |
| | 2024 | 2022 | PERSPECTUM, INC | 400 OYSTER POINT BLVD | SOUTH SAN FRANCISCO | CA | 94080-1979 | SAN MATEO | USA | U01FD007771 | Non-invasive quantification of liver health in NASH (N-QUAN): A prospective diagnostic accuracy study | 000 | 1 | FDA | 3/18/2024 | $0 |
| | 2024 | 2022 | PERSPECTUM, INC | 400 OYSTER POINT BLVD | SOUTH SAN FRANCISCO | CA | 94080-1979 | SAN MATEO | USA | U01FD007771 | Non-invasive quantification of liver health in NASH (N-QUAN): A prospective diagnostic accuracy study | 001 | 1 | FDA | 5/8/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $10,193 ) |
| | 2023 | 2023 | PERSPECTUM INC. | 400 OYSTER POINT BLVD STE. 435 | SOUTH SAN FRANCISCO | CA | 94080-1979 | SAN MATEO | USA | U01FD007771 | Non-invasive quantification of liver health in NASH (N-QUAN): A prospective diagnostic accuracy study | 001 | 1 | FDA | 11/9/2022 | $10,193 |
| | 2023 | 2022 | PERSPECTUM INC. | 400 OYSTER POINT BLVD STE. 435 | SOUTH SAN FRANCISCO | CA | 94080-1979 | SAN MATEO | USA | U01FD007771 | Non-invasive quantification of liver health in NASH (N-QUAN): A prospective diagnostic accuracy study | 000 | 1 | FDA | 10/26/2022 | $0 |
| | 2023 | 2019 | PERSPECTUM, INC | 400 OYSTER POINT BLVD | SOUTH SAN FRANCISCO | CA | 94080-1979 | SAN MATEO | USA | U01FD006880 | Towards full qualification of cT1 and PDFF as enrichment biomarkers for drug development: Characterising performance in the target population | 000 | 1 | FDA | 1/3/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $239,712 ) |
| | 2022 | 2022 | PERSPECTUM INC. | 400 OYSTER POINT BLVD STE. 435 | SOUTH SAN FRANCISCO | CA | 94080-1979 | SAN MATEO | USA | U01FD007771 | Non-invasive quantification of liver health in NASH (N-QUAN): A prospective diagnostic accuracy study | 000 | 1 | FDA | 8/9/2022 | $239,712 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2019 | PERSPECTUM INC. | 400 OYSTER POINT BLVD STE. 435 | SOUTH SAN FRANCISCO | CA | 94080-1979 | SAN MATEO | USA | U01FD006880 | Towards full qualification of cT1 and PDFF as enrichment biomarkers for drug development: Characterising performance in the target population | 000 | 1 | FDA | 1/5/2021 | $0 |
| | 2021 | 2019 | PERSPECTUM INC. | 400 OYSTER POINT BLVD STE. 435 | SOUTH SAN FRANCISCO | CA | 94080-1979 | SAN MATEO | USA | U01FD006880 | Towards full qualification of cT1 and PDFF as enrichment biomarkers for drug development: Characterising performance in the target population | 001 | 1 | FDA | 8/6/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2019 | PERSPECTUM DIAGNOSTICS INC. | 400 OYSTER POINT BLVD STE. 435 | SOUTH SAN FRANCISCO | CA | 94080-1979 | SAN MATEO | USA | U01FD006880 | Towards full qualification of cT1 and PDFF as enrichment biomarkers for drug development: Characterising performance in the target population | 001 | 1 | FDA | 8/4/2020 | $0 |
| | 2020 | 2019 | PERSPECTUM DIAGNOSTICS INC. | 400 OYSTER POINT BLVD STE. 435 | SOUTH SAN FRANCISCO | CA | 94080-1979 | SAN MATEO | USA | U01FD006880 | Towards full qualification of cT1 and PDFF as enrichment biomarkers for drug development: Characterising performance in the target population | 000 | 1 | FDA | 2/4/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $249,940 ) |
| | 2019 | 2019 | PERSPECTUM DIAGNOSTICS INC. | 400 OYSTER POINT BLVD STE. 435 | SOUTH SAN FRANCISCO | CA | 94080-1979 | SAN MATEO | USA | U01FD006880 | Towards full qualification of cT1 and PDFF as enrichment biomarkers for drug development: Characterising performance in the target population | 000 | 1 | FDA | 9/3/2019 | $249,940 |
|
|
